The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

BELOHLAVKOVA, Petra, Filip VRBACKY, Jaroslava VOGLOVA, Zdeněk RÁČIL, Daniela ŽÁČKOVÁ, Katerina HROCHOVA, Jana MALAKOVA, Jiří MAYER and Pavel ZAK. The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Archives of Medical Science. Poland: Termedia Publishing House, 2018, vol. 14, No 6, p. 1416-1423. ISSN 1734-1922. Available from: https://dx.doi.org/10.5114/aoms.2018.73538.

Basic information

• Original name: The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
• Authors: BELOHLAVKOVA, Petra (203 Czech Republic, guarantor), Filip VRBACKY (203 Czech Republic), Jaroslava VOGLOVA (203 Czech Republic), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Katerina HROCHOVA (203 Czech Republic), Jana MALAKOVA (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Pavel ZAK (203 Czech Republic).
• Edition: Archives of Medical Science, Poland, Termedia Publishing House, 2018, 1734-1922.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30204 Oncology
• Country of publisher: Poland
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 2.380
• RIV identification code: RIV/00216224:14110/18:00105953
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.5114/aoms.2018.73538
• UT WoS: 000448045000023
• Keywords in English: clinical response; imatinib; chronic myeloid leukemia; genetic polymorphisms
• Tags: 14110212, rivok
• Tags: International impact, Reviewed

Abstract

Introduction: Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes. Material and methods: In the present study we evaluated the association of eight polymorphisms in the seven genes CYP3A5*3 (rs776746), CYP3A4*1 (rs2740574), CYP2C9*3 (rs1057910), SLC22A1 (rs683369), ABCB1 (rs1045642, rs1128503), ABCG2 (rs2231142) and ABCC2 (rs717620) with imatinib plasma level and achieving an optimal clinical response in 112 CML patients (53 men and 59 women). Results: No association was found between the examined polymorphisms in rs776746, rs2740574, rs1057910, rs683369, rs1045642, rs1128503, rs2231142, rs717620 and the achieved imatinib plasma level. The influence of rs776746 (CYP3A5*3) on the achievement of a complete cytogenetic response (CCyR) at 6 months was borderline non-significant (p = 0.06). Furthermore, no association was demonstrated between rs776746 polymorphisms and the achievement of a major molecular response (MMR) at 12 or 18 months. Polymorphisms rs776746, rs2740574, rs1057910, rs683369, rs1045642, rs1128503, rs2231142, rs717620 showed no impact on the optimal therapeutic response. Conclusions: Despite the results of some other studies, no other polymorphism we analyzed was associated with imatinib plasma level or clinical response. The treatment outcomes cannot be predicted using the candidate gene approach and treatment decisions cannot be made according to the polymorphisms investigated in this study.